643 results on '"Lebbe, Celeste"'
Search Results
2. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
3. Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study
4. Diagnosis and treatment of dermatofibrosarcoma protuberans. European interdisciplinary guideline – update 2024
5. Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma
6. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2024
7. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024
8. Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma
9. BRAF and MEK inhibitors rechallenge after an adverse drug reaction in patients with cancer: A pharmacovigilance cohort study
10. When to stop immunotherapy for advanced melanoma: the emulated target trials
11. Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
12. Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database
13. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part II
14. Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I
15. Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them.
16. Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy
17. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy
18. The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects
19. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma
20. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023
21. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023
22. Hyperprogression in advanced melanoma is not restricted to immunotherapy
23. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice
24. Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma
25. Biomarqueurs prédictifs de la réponse à l’immunothérapie dans les mélanomes
26. Characteristics of circulating KSHV-infected viroblasts during active KSHV+ multicentric Castleman disease
27. Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation
28. Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort
29. CLAUDIUS Study: Risk of materno-fetal transmission of melanoma cells in pregnant women with high grade melanoma – A retrospective multicenter study and literature review
30. Immune-related generalised oedema – A new category of adverse events with immune checkpoint inhibitors
31. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial
32. An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases
33. The role of stereotactic radiotherapy in addition to immunotherapy in the management of melanoma brain metastases: results of a systematic review
34. Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 2022
35. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022
36. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022
37. PD-1 blockade with pembrolizumab in classic or endemic Kaposi's sarcoma: a multicentre, single-arm, phase 2 study
38. Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohort
39. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib
40. The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis
41. Un exemple de réorganisation dans le fonctionnement d’un Centre d’investigations cliniques en période de confinement national suite à la pandémie COVID-19
42. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
43. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
44. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
45. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response
46. Hematological immune related adverse events after treatment with immune checkpoint inhibitors
47. A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans
48. Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal
49. Deep cutaneous fungal infections in solid-organ transplant recipients
50. Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.